Unicycive Q2 net income $3.0M; OLC NDA on track for August 2024

Unicycive Therapeutics, Inc.

2024-Q2 EPS reported -$0.34

OLC pivotal trial: 1.4% discontinuation rate (evaluable) for treatment-related AEs; no SAEs.
Patient survey: 79% preferred OLC, 98% found it easy to take, 89% satisfied.
UNI-494 Phase 1 enrollment completed; data expected Q3 2024; new patent granted until 2040.
R&D expenses $4.9M (up $2.6M YoY); cash $41.8M, sufficient into 2026.
Diluted EPS loss $0.15; basic EPS $0.08 due to warrant liability fair value change.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.